高剂量吸入一氧化氮治疗COVID-19所致急性低氧性呼吸衰竭:多中心II期试验
这项多中心、单盲、随机对照平行组II期试验纳入193例COVID-19肺炎机械通气成人,干预组吸入一氧化氮80 ppm持续48小时,对照组接受常规治疗(无安慰剂)。48小时PaO2/FiO2平均变化干预组28.3 mmHg、对照组21.4 mmHg(平均差39.1 mmHg;95%CrI 18.1至60.3)。28天达到PaO2/FiO2>300 mmHg的比例干预组27.7%、对照组17.2%(风险比2.03;95%CrI 1.11至3.86)。达到PaO2/FiO2>300 mmHg的时间、通气时长及28天和90天死亡率无差异,未报告严重不良事件。
要点
- COVID-19机械通气成人吸入一氧化氮80 ppm持续48小时,48小时PaO2/FiO2平均变化28.3 mmHg,对照组21.4 mmHg,平均差39.1 mmHg(95%CrI 18.1至60.3)。
- 28天达到PaO2/FiO2>300 mmHg的比例:一氧化氮组27.7% vs 对照组17.2%,风险比2.03(95%CrI 1.11至3.86)。
- 达到PaO2/FiO2>300 mmHg的时间:一氧化氮组平均8.7天 vs 对照组8.4天(平均差0.44;95%CrI 23.63至4.53)。
- 通气时长、28天死亡率和90天死亡率两组无差异,未报告严重不良事件。
适用人群与场景
- COVID-19肺炎、机械通气的成人患者,纳入改良意向性分析共193例。
处置流程与药物剂量
- 干预组吸入一氧化氮80 ppm持续48小时;对照组接受常规治疗(无安慰剂)。
研究设计与关键结果
- II期、多中心、单盲、随机对照平行组试验,193例纳入改良意向性分析;主要终点48小时PaO2/FiO2平均变化:干预组28.3 mmHg vs 对照组21.4 mmHg,平均差39.1 mmHg(95%CrI 18.1至60.3)。
- 达到PaO2/FiO2>300 mmHg的平均时间:干预组8.7天 vs 对照组8.4天,平均差0.44(95%CrI 23.63至4.53)。
- 28天达到PaO2/FiO2>300 mmHg的比例:干预组27.7% vs 对照组17.2%,风险比2.03(95%CrI 1.11至3.86)。
- 通气时长、28天死亡率和90天死亡率两组无差异;未报告严重不良事件。
证据类型、等级与局限
- 证据类型:多中心、单盲、随机对照平行组II期试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,高剂量吸入一氧化氮(80 ppm持续48小时)与常规治疗相比可改善COVID-19急性低氧性呼吸衰竭成人48小时PaO2/FiO2。
- 通气时长及28天、90天死亡率无差异,未报告严重不良事件。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: The effects of high-dose inhaled nitric oxide on hypoxemia in coronavirus disease (COVID-19) acute respiratory failure are unknown. Objectives: The primary outcome was the change in arterial oxygenation (PaO2/FiO2) at 48 hours. The secondary outcomes included: time to reach a PaO2/FiO2.300mmHg for at least 24 hours, the proportion of participants with a PaO2/FiO2.300mmHg at 28 days, and survival at 28 and at 90 days. Methods: Mechanically ventilated adults with COVID-19 pneumonia were enrolled in a phase II, multicenter, single-blind, randomized controlled parallel-arm trial. Participants in the intervention arm received inhaled nitric oxide at 80 ppm for 48 hours, compared with the control group receiving usual care (without placebo). Measurements and Main Results: A total of 193 participants were included in the modified intention-to-treat analysis. The mean change in PaO2/FiO2 ratio at 48 hours was 28.3mmHg in the intervention group and 21.4mmHg in the control group (mean difference, 39.1mmHg; 95% credible interval [CrI], 18.1 to 60.3). The mean time to reach a PaO2/FiO2.300mmHg in the interventional group was 8.7 days, compared with 8.4 days for the control group (mean difference, 0.44; 95% CrI, 23.63 to 4.53). At 28 days, the proportion of participants attaining a PaO2/FiO2.300mmHg was 27.7% in the inhaled nitric oxide group and 17.2% in the control subjects (risk ratio, 2.03; 95% CrI, 1.11 to 3.86). Duration of ventilation and mortality at 28 and 90 days did not differ. No serious adverse events were reported. Conclusions: The use of high-dose inhaled nitric oxide resulted in an improvement of PaO2/FiO2 at 48 hours compared with usual care in adults with acute hypoxemic respiratory failure due to COVID-19.
参考来源
- Di Fenza R, Shetty NS, Gianni S, et al. High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure Due to COVID-19: A Multicenter Phase II Trial. Am J Respir Crit Care Med. 2023. PMID: 37774011. doi:10.1164/rccm.202304-0637OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。